Trial to Assess Chelation Therapy in Critical Limb Ischemia
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy,
edetate disodium-based chelation of environmentally acquired toxic metals, to reduce
cardiovascular events including amputation in high-risk diabetic patients.